KOA SHOJI HOLDINGS CO.,LTD. [9273.T]
TOKYO, May 11 (Pulse News Wire) – KOA Shoji Holdings CO.,LTD. (9273.T) reported strong third-quarter results for the fiscal year ending June 2026.
Revenue increased by 4.0%, reaching ¥3.713 billion compared to the same period last year. Operating profit rose by 4.5% to ¥800 million, reflecting robust performance across segments. In the pharmaceutical products segment, sales of prefilled syringe formulations and anticancer agents showed steady growth, while solid-dose medications faced competition leading to reduced sales. In contrast, the active pharmaceutical ingredients (API) segment saw significant gains due to increased market penetration of recently launched products and higher transaction volumes. Looking ahead, the company expects continued growth driven by its API segment, aiming to achieve a consolidated operating income target of ¥80 billion by June 2030.
Despite challenges such as price adjustments in the drug pricing system, KOA Shoji anticipates relatively contained impacts on overall group performance. For the upcoming fiscal year, the company plans to increase dividend payments per share to ¥18, up from the initial expectation of ¥16, based on favorable earnings trends. The dividend payout ratio remains consistent with past guidance, targeting more than 20%. KOA Shoji also highlighted ongoing investment activities, including the construction of the second Kuwana factory proceeding as scheduled, contributing to capital expenditures totaling ¥1.735 billion. Additionally, the purchase of foreign-denominated convertible bonds further bolstered investments and other assets.
🟡 Confidence: Standard AI-translated content.